An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Sueta, Aiko ^a,b   Yamamoto, Yutaka ^a,b   Yamamoto Ibusuki, Mutsuko ^a   Hayashi, Mitsuhiro ^a   Takeshita, Takashi ^a   Yamamoto, Satoko ^a   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GENOMIC DNA; INOSITOL POLYPHOSPHATE 4 PHOSPHATASE II; PACLITAXEL; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL-3,4-BISPHOSPHATE 4-PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; GENE DOSAGE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; MUTATION RATE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; BREAST; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84919909647     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116054     Document Type: Article

References (47)

1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
2. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36.
3. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, et al. (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29: 3366-3373.
4. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
5. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, et al. (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318-324.
6. Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 15: 7479-7491.
7. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
8. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
9. Jones N, Bonnet F, Sfar S, Lafitte M, Lafon D, et al. (2013) Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer 133: 323-334.
10. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, et al. (2009) Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16: 115-125.
11. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
12. Network TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
13. Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, et al. (2012) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23: 2034-2042.
14. Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, et al. (2013) Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 105: 960-967.
15. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, et al. (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128: 447-456.
16. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, et al. (2006) PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94: 247-252.
17. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, et al. (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177: 1647-1656.
18. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, et al. (2009) EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 20: 648-654.
19. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
20. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, et al. (2013) Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A 110: 14372-14377.
21. Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, et al. (2012) Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 18: 6784-6791.
22. Wang HL, Lopategui J, Amin MB, Patterson SD (2010) KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv Anat Pathol 17: 23-32.
23. Isler JA, Vesterqvist OE, Burczynski ME (2007) Analytical validation of genotyping assays in the biomarker laboratory. Pharmacogenomics 8: 353-368.
24. Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32: 579-586.
25. Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, et al. (2014) Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20: 2643-2650.
26. Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, et al. (2013) Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 108: 1807-1809.
27. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, et al. (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29: 166-173.
28. Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, et al. (2014) PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. J Clin Oncol 32: 3212-3220.
29. Loibl S (2013) PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant. 36th SanAntonio Breast Cancer Symposium, Abstract S4-06.
30. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, et al. (2014) CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors. Cancer Cell 26: 136-149.
31. Gabriel N. Hortobagyi, MJP-G, Hope S. Rugo, Howard A. Burris, et al. (2013) Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 31(suppl; abstr LBA509).
32. Isabelle Treilleux MA, Claire Cropet, Jean-Marc Ferrero, Sophie Abadie Lacourtoisie, Dominique Spaeth, et al. (2013) Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): Final results of the TAMRAD trial translational study.2013 ASCO Annual Meeting J Clin Oncol 31(suppl; abstr 510).
33. Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, et al. (2012) Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res 40: e82.
34. Yung TK, Chan KC, Mok TS, Tong J, To KF, et al. (2009) Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076-2084.
35. Wu G, Xing M, Mambo E, Huang X, Liu J, et al. (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7: R609-616.
36. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
37. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, et al. (2010) PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126: 1121-1131.
38. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, et al. (2012) Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119: 7-15.
39. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
40. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM (2011) INPP4B: the new kid on the PI3K block. Oncotarget 2: 321-328.
41. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, et al. (2011) Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 71: 572-582.
42. Perez-Lorenzo R, Gill KZ, Shen CH, Zhao FX, Zheng B, et al. (2014) A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. J Invest Dermatol 134: 1359-1368.
43. Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, et al. (2010) Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A 107: 22231-22236.
44. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.
45. Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, et al. (2012) Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens. Breast Cancer 20: 262-270.
46. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, et al. (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103: 1656-1664.
47. Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, et al. (2010) Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 18: 371-374.